FDA Recalls 3,744 Bottles of Generic Blood Pressure Meds Over Dissolution Failures

Key points

• Macleods Pharma USA initiated a voluntary recall on Oct. 7 for 3,528 30-count and 216 90-count bottles of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide tablets.
• The FDA classified the recall as Class II on Oct. 26, indicating potential temporary adverse health consequences but a remote likelihood of serious harm.
• The recall was triggered by 'failed dissolution specifications,' meaning the tablets did not dissolve as required during testing, potentially rendering the medication ineffective for lowering blood pressure.
• Affected lots include 12251163A (NDC 33342-246-07) and 12251163B (NDC 33342-246-10), both expiring May 31, 2027.
• Brand-name Tribenzor is not included in the recall, but patients using generic versions should verify their specific lot numbers.

Background

This recall follows a series of similar FDA actions regarding blood pressure medications in 2026. In September, the FDA classified a Class II recall for 13,567 bottles of chlorthalidone tablets manufactured by Inventia Healthcare Ltd. due to dissolution failures. Additionally, in late October, the FDA issued a Class III recall for over 21,000 bottles of Viatris Inc. telmisartan and amlodipine tablets, which contained excess active ingredients. These events highlight ongoing quality control issues in the generic pharmaceutical supply chain for hypertension treatments.

How outlets are covering it

Fox Business and Yahoo both reported the recall as a Class II action, emphasizing that the likelihood of serious health consequences is remote. USA Today provided additional context, noting that the recalled medication is a generic version of the brand-name drug Tribenzor and advising patients to check their bottles to ensure they are not using the affected generic. While all sources agree on the dissolution failure as the cause, USA Today highlighted the importance of consulting healthcare providers before discontinuing use, whereas Fox Business noted that Macleods Pharma did not immediately respond to comment requests. The secondary source from PhillyBurbs focused on a separate, concurrent recall of Viatris products, illustrating the broader trend of blood pressure medication recalls in late 2026.

Why it matters

Patients relying on generic blood pressure medications must verify their lot numbers to ensure safety. Dissolution failures can lead to ineffective treatment, potentially allowing high blood pressure to go uncontrolled. This recall underscores the importance of checking medication labels and consulting healthcare providers for guidance on continuing or switching treatments.

What to watch

The recall remains ongoing as of early November 2026. Patients with affected lots should contact their healthcare providers or pharmacists for alternative medications. The FDA continues to monitor the situation, and Macleods Pharma is expected to provide further updates on the recall process and potential refunds.